عرض بسيط للتسجيلة

المؤلفAl-Badriyeh, Daoud
المؤلفAlabbadi, Ibrahim
المؤلفFahey, Michael
المؤلفAl-Khal, Abdullatif
المؤلفZaidan, Manal
تاريخ الإتاحة2021-03-18T10:15:10Z
تاريخ النشر2016
اسم المنشورClinical Therapeutics
المصدرScopus
الرقم المعياري الدولي للكتاب1492918
معرّف المصادر الموحدhttp://dx.doi.org/10.1016/j.clinthera.2016.03.004
معرّف المصادر الموحدhttp://hdl.handle.net/10576/17910
الملخصPurpose The formulary inclusion of proton pump inhibitors (PPIs) in the government hospital health services in Qatar is not comparative or restricted. Requests to include a PPI in the formulary are typically accepted if evidence of efficacy and tolerability is presented. There are no literature reports of a PPI scoring model that is based on comparatively weighted multiple indications and no reports of PPI selection in Qatar or the Middle East. This study aims to compare first-line use of the PPIs that exist in Qatar. The economic effect of the study recommendations was also quantified. Methods A comparative, evidence-based multicriteria decision analysis (MCDA) model was constructed to follow the multiple indications and pharmacotherapeutic criteria of PPIs. Literature and an expert panel informed the selection criteria of PPIs. Input from the relevant local clinician population steered the relative weighting of selection criteria. Comparatively scored PPIs, exceeding a defined score threshold, were recommended for selection. Findings Weighted model scores were successfully developed, with 95% CI and 5% margin of error. The model comprised 7 main criteria and 38 subcriteria. Main criteria are indication, dosage frequency, treatment duration, best published evidence, available formulations, drug interactions, and pharmacokinetic and pharmacodynamic properties. Most weight was achieved for the indications selection criteria. Esomeprazole and rabeprazole were suggested as formulary options, followed by lansoprazole for nonformulary use. The estimated effect of the study recommendations was up to a 15.3% reduction in the annual PPI expenditure. Robustness of study conclusions against variabilities in study inputs was confirmed via sensitivity analyses. Implications The implementation of a locally developed PPI-specific comparative MCDA scoring model, which is multiweighted indication and criteria based, into the Qatari formulary selection practices is a successful evidence-based cost-cutting exercise. Esomeprazole and rabeprazole should be the first-line choice from among the PPIs available at the Qatari government hospital health services. 2016 Elsevier HS Journals, Inc.
راعي المشروعThe work was reviewed and funded by the National Priority Research Programme, Qatar National Research Fund (NPRP-5-284-3-083), Qatar Foundation, Doha, Qatar. No funding from a pharmaceutical industry was received.
اللغةen
الناشرExcerpta Medica Inc.
الموضوعeconomics
multi-indication
multicriteria
proton pump inhibitors
Qatar
scoring model
selection
العنوانMulti-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar
النوعArticle
الصفحات1158-1173
رقم العدد5
رقم المجلد38
dc.accessType Abstract Only


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة